Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
about
Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysisNAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.Biliary drainage improves the predictive value of modified Glasgow Prognostic Scores in inoperable pancreatic cancer.Prognostic factors associated with early mortality after surgical resection for pancreatic adenocarcinoma.Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma.Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis.Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis.Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancerClinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter.Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib.Neutrophil-lymphocyte ratio in children with familial Mediterranean fever: Original article.A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure.Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma.Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer.Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia.Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio can predict the severity of gallstone pancreatitis.Prognostic role of the pre-treatment platelet-lymphocyte ratio in pancreatic cancer: a meta-analysis.Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients.Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis.Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma.Prognostic role of platelet to lymphocyte ratio in pancreatic cancers: A meta-analysis including 3028 patients.Novel Mortality Markers for Critically Ill Patients.The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma.Prognostic value of the Glasgow Prognostic Score in renal cell carcinoma: a meta-analysis.Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies.The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies.Increased platelet-to-lymphocytes ratio is associated with poor long-term prognosis in patients with pancreatic cancer after surgery.Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio.Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.Preoperative platelet-lymphocyte ratio is an independent prognostic factor in ampullary carcinoma following pancreaticoduodenectomy
P2860
Q28083684-0DF66F78-B878-4FA6-A47F-5D5AFF935DAEQ33435134-0C4AA473-1AF7-4586-A55B-0986637C2906Q33618490-0A8B3FA4-26C6-4C3A-B7FA-0129275396B9Q33762053-E421A995-6191-409E-973B-CAD6A1AB532AQ33828786-44D9F5CA-D541-4E30-8A6C-DEEFAADBA3C9Q35820957-EB637946-75A5-482C-9385-3159F441ACDEQ35858209-A57D67AD-3E10-47D4-930E-45D141E3A99EQ35905788-15D67197-3168-4228-B7DA-9C0282337648Q36390876-C9ACBFF5-55E4-4B9A-AE5E-116C7EA5BD2AQ36825610-ACAD3554-8C11-4E74-A9E3-9FF8E0A2EDDAQ36891938-6398F1E8-F28D-4DE9-94B2-C53394DFCCEBQ37089422-D942D19E-0DA5-46F2-9984-38D9AB83B052Q40167665-8DB67D42-65F8-4E35-8D08-7BDD640C41DAQ40277757-DF44731B-BA44-4E39-A24F-340F2C41CDA1Q40909577-EF2E43BF-DC30-4FED-9C74-C8B64E472A03Q40914627-D2C66F07-A248-4F65-AF00-E8A51E1B205BQ41644002-4A24B4FD-9B66-4E9C-B29A-48808210B7BCQ47098673-39EA07B0-1924-4A44-A1FF-B0EEFD3B534EQ47108053-63947045-DB9F-4C4E-9BD2-01DAE1B9E39EQ47141106-F1990CD8-B44E-40AB-A694-F0BC2C831DB4Q48164452-4199856D-9F44-495F-8473-A56DEF606679Q49323153-8CD10E71-C09B-48EC-A174-DA2806592049Q49487440-DD84A7C1-277C-44E5-8743-D1286DD560B6Q49513468-5F59AF7F-F198-492D-8847-DD4522082AC1Q49658183-7BDA7A05-224C-4680-905D-D57632C20C3CQ49712241-9819CC67-2ED0-4124-A8D0-3CE28DD0E64EQ50044542-69514BF4-9884-4C35-84B1-57DCFCA0FE34Q50158378-3E930CDB-07F5-4278-8F18-513A1034A901Q50703561-CB685FCC-96AB-494B-88A8-3EDA2CBBED07Q51465750-25FC525B-00BB-42A1-A5A3-A33E390151DCQ52579384-DED72949-DF63-4C1D-AEF9-45A904B2B02CQ52605888-F778915B-6268-4B16-97C7-1D53254E51B8Q53548609-8CF38352-8AED-4F63-938F-D922455B2AA1Q55404961-65D6E679-2E74-42F0-9272-F9E77F0DB9B8Q55441827-0AC6D973-ECE0-4974-9C6E-CFBEEA6486D3Q55492890-4E6FB86E-4630-46DF-A5A2-8C202239825DQ58794884-8D482679-45EE-49F0-A6C1-2382F5D093D9
P2860
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@en
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@nl
type
label
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@en
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@nl
prefLabel
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@en
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@nl
P2093
P2860
P356
P1476
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
@en
P2093
P2860
P304
P356
10.1111/IMJ.12453
P577
2014-07-01T00:00:00Z